Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF

In this expert commentary, Toby Maher, MD, PhD, discusses the evolving treatment landscape in progressive pulmonary fibrosis (PPF) and the potential implications of the longer-term FIBRONEER-ILD trial findings. He explores how nerandomilast may address key unmet needs in PPF, with a focus on disease progression, clinically meaningful outcomes, treatment sequencing, and the broader impact on patients, providers, and health care systems.